NEWS

  FOR IMMEDIATE RELEASE January 12, 2023 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629   CAZENOVIA, NY – NCODA, a non-profit organization whose Mission is to empower the medically-integrated oncology team to deliver positive, patient-centered outcomes – announces the appointment of three new members to its executive council: William Mitchell, MD, Lance Ortega, MBA, BSN, RN, […]

FOR IMMEDIATE RELEASE December 21, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629   CAZENOVIA, NY – NCODA, Inc. is excited to announce the creation of a new and innovative Accredited Medically-Integrated Oncology Pharmacy (MIOP) Residency Program. NCODA worked with cancer centers throughout the United States to provide the program framework and accreditation for this unique […]

FOR IMMEDIATE RELEASE December 16, 2022 Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org In a year that has seen plenty of legislative and political uncertainty, NCODA is proud of the Legislative & Policy Advisory Committee (LPAC) for maintaining their steadfast goal to educate our membership and shed […]

12/12/2022 SAN DIEGO, Dec. 12, 2022 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI™ (adagrasib), a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received […]

FOR IMMEDIATE RELEASE December 8, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@ncoda.org 813-843-1629   CAZENOVIA, NY – The need for oncology-focused pharmacy technician training has increased exponentially with advancements in the oral oncolytic landscape. To empower the entire medically-integrated oncology team and ensure an advanced level of patient care, NCODA’s Oncology Pharmacy Technician Association (OPTA) has […]

Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy alone, in a patient population with a wide range of disease characteristics Second advanced NSCLC indication expands patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy  irrespective of PD-L1 expression levels TARRYTOWN, N.Y., Nov. 8, 2022 /PRNewswire/ — Regeneron Pharmaceuticals, […]

TECVAYLI™, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed […]

Cazenovia, NY (Oct 13, 2022) – With a recent policy change made to The New York State Department of Health’s (NYSDOH) Medicaid Pharmacy Program that prevents patients from obtaining their oral medication through their physician dispensary, practice leaders from New York Oncology Hematology (NYOH) immediately took action and led efforts to bring attention to this […]

The U.S. Food and Drug Administration approved the use of IMBRUVICA for the treatment of pediatric patients one year and older with cGVHD after failure of one or more lines of systemic therapy This is the first approved treatment option for children with cGVHD under 12 years of age and the only Bruton’s tyrosine kinase […]

FOR IMMEDIATE RELEASE September 13, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org On the afternoon of Monday, September 12, President Biden arrived in Boston and made his way to the John F. Kennedy (JFK) Presidential Library. His visit […]

Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement August 26, 2022 – This marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor […]

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022 – Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints – – NDA Submission to the U.S. FDA […]